Supplementary Fig. S1






















GR011: 5-FU
IC50=9.11μM
IC80>100μM
(%)
120
100
80
60
40
20
0
0.01
0.1
1
10
100
(μM)


GR012: Gemicitabine
IC50=0.167μM
IC80>100μM
(%)
120
100
80
60
40
20
0
0.01
0.1
1
10
100
(μM)


GR013: Melphalan
IC50=32.0μM
IC80=87.8μM
(%)
120
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
(μM)


GR014: Mitomycin C
IC50=803nM
IC80>3μM
(%)
140
120
100
80
60
40
20
0
1
10
100
1000
10000
(nM)


GR015: Oxaliplatin
IC50=0.189μM
IC80=2.03μM
(%)
70
60
50
40
30
20
10
0
0.01
0.1
1
10
100
(μM)


GR016: Bleomycin
IC50=0.507μg/ml
IC80=31.6μg/ml
(%)
80
70
60
50
40
30
20
10
0
0.01
0.1
1
10
100
(μg/ml)


GR017: Actinomycin D
IC50=0.561nM
IC80=12.9nM
(%)
100
90
80
70
60
50
40
30
20
10
0
0.01
0.1
1
10
100
(nM)


GR018: Neocarzinostatin
IC50=0.564μg/ml
IC80=1.96μg/ml
(%)
160
140
120
100
80
60
40
20
0
1
10
100
1000
10000
(ng/ml)


GR019: Methotrexate
IC50=46.8nM
IC80>3000nM
(%)
160
140
120
100
80
60
40
20
0
1
10
100
1000
10000
(nM)


GR020: 6-Mercaptopurine
IC50=49.2μM
IC80>100μM
(%)
120
100
80
60
40
20
0
0.01
0.1
1
10
100
(μM)


GR021: Temsirolimus
IC50=11.6μM
IC80=26.6μM
(%)
70
60
50
40
30
20
10
0
0.01
0.1
1
10
100
(μM)


GR022: Everolimus
IC50=16.0μM
IC80=26.9μM
(%)
80
70
60
50
40
30
20
10
0
1
10
100
(μM)


GR023: PP242
IC50=0.521μM
IC80=3.15μM
(%)
120
100
80
60
40
20
0
0.01
0.1
1
10
100
(μM)


GR024: Nimustine
IC50=659μM
IC80>800μM
(%)
120
100
80
60
40
20
0
1
10
100
1000
(μM)


GR025: SN38
IC50=0.140μM
IC80=1.72μM
(%)
80
70
60
50
40
30
20
10
0
0.01
0.1
1
10
100
(μM)


GR026: Camptothecin
IC50=146nM
IC80=860nM
(%)
100
90
80
70
60
50
40
30
20
10
0
1
10
100
1000
10000
(nM)


GR027: Topotecan
IC50=0.409μM
IC80=2.44μM
(%)
100
90
80
70
60
50
40
30
20
10
0
0.01
0.1
1
10
100
(μM)


GR028: Doxorubicin
IC50=183nM
IC80=1.26μM
(%)
120
100
80
60
40
20
0
1
10
100
1000
10000
(nM)


GR029: Etoposide
IC50=6.24μM
IC80=18.3μM
(%)
120
100
80
60
40
20
0
0.01
0.1
1
10
100
(μM)


GR030: Mitoxantrone
IC50=89.3nM
IC80=0.564μM
(%)
100
80
60
40
20
0
-20
0.01
0.1
1
10
100
(μM)



Supplementary Fig. S1: Dose-response curves for 35 anticancer compounds. Experiments were replicated four times for each compound and the average growth inhibitions were plotted. IC50 and IC80 values were estimated by using linear regression models.